E.J. Soini et al. Current Medical Research & Opinion 2010;26:25-36

E.J. Soini et al. Current Medical Research & Opinion 2010;26:25-36

Model’s flow-chart

E.J. Soini et al. Current Medical Research & Opinion 2010;26:25-36

Drugs (excluding VAT), resources, and CHD-related morbidity management (state costs)

E.J. Soini et al. Current Medical Research & Opinion 2010;26:25-36

Non-fatal and fatal event costs (gamma distribution assumed in the probabilistic analysis)

E.J. Soini et al. Current Medical Research & Opinion 2010;26:25-36

Base-case results

E.J. Soini et al. Current Medical Research & Opinion 2010;26:25-36

Cost-effectiveness acceptability frontier (CEAF) for men (a) and women (b) without and with diabetes

using generic S40 (dashed black line) or S40+EZ10

E.J. Soini et al. Current Medical Research & Opinion 2010;26:25-36

Incremental cost-effectiveness ratios (ICER) as the function of baseline LDL-C and most cost-effective medications